MedTrace Logo

Safety Study of BMS-816336 in Healthy Male Subjects

NCT00979368 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2011-02-23

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics following single oral doses of BMS-816336 in healthy male subjects.

Conditions

Interventions

DRUG

BMS-816336

Suspension, Oral, 15 mg Active, Once on Day 1 only, 4 days

DRUG

BMS-816336

Suspension, Oral, 60 mg Active, Once on Day 1 only, 4 days

DRUG

BMS-816336

Suspension, Oral, 180 mg Active, Once on Day 1 only, 4 days

DRUG

BMS-816336

Suspension, Oral, 450 mg Active, Once on Day 1 only, 4 days

DRUG

BMS-816336

Suspension, Oral, 900 mg Active, Once on Day 1 only, 4 days

DRUG

Placebo

Suspension, Oral, 0 mg, Once on Day 1 only, 4 days

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2010-02-28
Completion
2010-02-28

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00979368 on ClinicalTrials.gov